Cardlytics Inc (NASDAQ:CDLX) Receives $48.86 Consensus PT from Analysts

Shares of Cardlytics Inc (NASDAQ:CDLX) have earned a consensus rating of “Buy” from the nine brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $46.50.

A number of analysts have recently commented on CDLX shares. JPMorgan Chase & Co. cut Cardlytics from an “overweight” rating to a “neutral” rating and set a $58.00 price target for the company. in a research note on Thursday, November 14th. They noted that the move was a valuation call. Zacks Investment Research cut Cardlytics from a “buy” rating to a “hold” rating in a research report on Thursday. Craig Hallum assumed coverage on shares of Cardlytics in a research note on Monday. They set a “buy” rating and a $75.00 price target for the company. Raymond James lifted their price objective on shares of Cardlytics from $40.00 to $53.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, ValuEngine lowered shares of Cardlytics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd.

In related news, CEO Scott D. Grimes sold 250,000 shares of Cardlytics stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $32.30, for a total transaction of $8,075,000.00. Also, Director Mark A. Johnson sold 100,000 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $32.30, for a total value of $3,230,000.00. Over the last ninety days, insiders bought 316,475 shares of company stock worth $11,914,849 and sold 963,561 shares worth $40,132,784. 21.90% of the stock is currently owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the business. FMR LLC boosted its stake in shares of Cardlytics by 2.3% during the 1st quarter. FMR LLC now owns 3,284,572 shares of the company’s stock worth $54,327,000 after acquiring an additional 72,847 shares during the period. BlackRock Inc. lifted its holdings in Cardlytics by 94.2% during the 2nd quarter. BlackRock Inc. now owns 903,619 shares of the company’s stock valued at $23,476,000 after purchasing an additional 438,215 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Cardlytics by 46.1% during the 2nd quarter. Vanguard Group Inc. now owns 755,132 shares of the company’s stock valued at $19,618,000 after purchasing an additional 238,211 shares during the last quarter. Grantham Mayo Van Otterloo & Co. LLC bought a new position in Cardlytics during the second quarter worth $10,392,000. Finally, UBS Oconnor LLC boosted its position in Cardlytics by 12.1% during the second quarter. UBS Oconnor LLC now owns 344,354 shares of the company’s stock worth $8,946,000 after purchasing an additional 37,153 shares during the period. Hedge funds and other institutional investors own 93.17% of the company’s stock.

Shares of CDLX traded down $2.35 on Tuesday, reaching $61.35. 472,897 shares of the company’s stock were exchanged, compared to its average volume of 352,988. The stock has a market capitalization of $1.45 billion, a P/E ratio of -28.67 and a beta of 1.71. The business has a 50 day moving average price of $47.81 and a two-hundred day moving average price of $34.42. Cardlytics has a 12 month low of $9.80 and a 12 month high of $65.43.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.31. Cardlytics had a negative net margin of 17.01% and a negative return on equity of 44.53%. The firm had revenue of $56.42 million for the quarter, compared to analysts’ expectations of $50.02 million. During the same period last year, the firm earned ($0.15) earnings per share. The business’s revenue for the quarter was up 63.2% on a year-over-year basis. As a group, equities analysts forecast that Cardlytics will post -1.01 EPS for the current fiscal year.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Featured Article: Consumer behavior in bull markets

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.